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Abstract:  
Objectives: This is a descriptive, prospective, cross-sectional, hospital based study to determine the 
prevalence of Hepatitis B Virus and Hepatitis C Virus among Human Immunity deficiency Virus infected 
subjects in the Gezira State of central Sudan. 
Materials and Methods: The study was carried out on HIV infected subjects attending Wad Medani 
VCT/ART centre from Dec. 2010 to March 2011. Epidemiological and demographic characteristics were 
recorded and participants were interviewed for risk factors of viral hepatitis infection. Blood samples 
were then collected and tested for HBsAg and HCV antibodies. 
Results: A total of 50 subjects were screened with a mean age of 36.39±13.57, 52% were males, HBsAg 
and HCV antibodies were reactive in 8% and 0% (none) of the studied group, respectively. 
Conclusion: This study shows that the prevalence of HBV/HIV co-infection is consistent with both 
regional and global rates, while HCV/HIV co-infection is low in the studied group. 
صخلم: 
:فادهلأا  حتاصلإا عْ٘ش ذٗذحذ باِرلاتذثكلا وحلآْ ( بHBV( ج ّ )HCV ةسركولا حعاٌولا صْع ٔوحت ي٘تاصولا ٔضشولا طسّ )
(HIV   حٗلاْت ).ىادْسلا طسّ جشٗضجلا 
لاىضرم :لئاسولا و ذ ح٘فصّ حساسد ٍزُٔفشرسولا ٔلع حٌ٘ثه ح٘عطقه ح٘عقْ حعاٌولا صْع ٔوحت ي٘تاصولا ٔضشولا ٖف حساسذلا دٗشجأ .
ٔفشرسه ٔلع يٗددشرولا ةسركولا ضكشه ًٖذهدّ ART/VCT  شثوسٗد ي٘ت جشرفلا ٖف2010 طساه ٔرح ّ م2011 مخاض٘ولا  ح٘ئاتْلا
ّهلاولاح  جسْطخلا لهاْع حفشعول ي٘كساشولا حٌٗاعه دوذ ّ خذصس حً٘اكسلال اِصحف نذ ّ مذلا خاٌ٘ع دعوج .ذثكلا ٔوحت حتاصلإ
لل ٖعاٌولا داضوHBsAg  ج ٔوح داضه ّHCV . 
:جئاتنلا   عْوجه00  اِحسه نذ حلاح شوع طسْروت33.33 ± 13.01  حثسً . ًاك سْكر د02% .خلااحلا يه  خاداضهHBsAg  
ّHCV    ٖف حلعافره دًاك8 ّ %0% )ذجْٗ لا( .ٖلاْرلا ٔلع 
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ةصلاخلا :حتاصلاا عْ٘ش حساسذلا دحضّأ  ذثكلا باِرلاتوحلاْ ٓ بHBV  ي٘تاصولا طسّHIV ٔشاورذ  حتاصلإا عْ٘ش خلاذعه عه
 ح٘ولاعلا ّ ح٘و٘لقلإا َتاصلاا اوٌ٘ت . ٔوحلإذثكلا ( جHCV) حسّسذولا َعْوجولا ٔف ف٘عض ىاك. 
Key Words: Hepatitis B/HIV co-infection, Hepatitis C/HIV co-infection, risk factors.  
 
Introduction: 
In June 1981, the first cases of what was later called acquired immunodeficiency syndrome (AIDS) in the 
United States were reported in Morbidity and Mortality Weekly Report (MMWR) 
(1)
. The prevalence of 
co-infection with either Hepatitis C Virus or Hepatitis B Virus varies depending on the patient's risk 
factors for HIV acquisition
(2)
.Over two billion people worldwide have evidence of previous or current 
hepatitis B virus (HBV) infection. Risk factors for infection include blood transfusion, sexual intercourse, 
intravenous drug abuse, vertical and horizontal transmission of the virus 
(3)
.Sudan is classified among 
countries with a high hepatitis B surface antigen (HBsAg) endemicity of more than 8% 
(4)
.The few studies 
on HCV infection in Sudan demonstrated a low seroprevalence ranging from 2.2% in the Gezira State
 (5)
, 
an area endemic with schistosomiasis to 4.8% in patients with schistosomal periportal fibrosis. Genotype 
4 was the commonly isolated
(6)
. There are no previous studies on HBV/ HCV co-infection in HIV 
infected patients, in Central Sudan. So the objective of this study was to determine the prevalence of 
Hepatitis B Virus (HBV) and Hepatitis C virus (HCV) among Human Immunodeficiency Virus (HIV) 
infected subjects. 
 
Materials and Methods: 
Study population: 
The study was conducted in Wad Medani Voluntary Counseling and Testing (VCT)/Antiretroviral 
Therapy (ARV) Centre which is located in Wad Medani Teaching Hospital. Wad Medani is the capital of 
Gezira State, which covers 8,901 Squares Kilometers, with a population of 3,750,000(2009 Census).The 
centre was established in 2005 as a voluntary counseling and testing centre(VCT), it provides: 
confidential testing and counseling for clients and suspected cases, health care, treatment and follow-up. 
In January 2006, the centre started to provide antiretroviral therapy (ART). 
Study design and technique: 
The study was a descriptive, prospective, cross-sectional hospital based. It was carried out in the period 
from the 23
rd
 of December 2010 to the 19
th
 of March 2011.All clients and patients who were positive for 
HIV (having their blood tested by ELISA, Biorex, UK) coming for regular follow-up, making a total of 
50 cases, were included in the study. Two of them were on Highly Active Antiretroviral Therapy 
(HAART). Those who were negative for HIV were excluded from the study. All patients had their blood 
tested for HBsAg by ELISA (Fourth generation, Biorex, UK).All patients had their blood tested for the 
presence of HCV Abs by ELISA.  
 Statistical analysis: 
Demographic and clinical data including the laboratory results were collected by a questionnaire. Data 
were analyzed by using the Statistical Package for Social Sciences (SPSS) version 11. The χ2 test with 
Yates correction was used to compare proportions. Odd ratios (OR) with 95% confidence intervals 
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(95%CI) were calculated either directly or by the Mantel-Haenszel
’
s methods for stratified OR. Results 
were tabulated and presented in simple percentage forms. 
Ethical Clearance: 
An informed consent was obtained from all study subjects or from the parents when children were tested, 
as well as permission from the State Coordinator of SNAP. Ethical clearance for the study was then 
obtained from Ethical Clearance Committee of the Faculty of Medicine, University of Gezira. 
 
Results: 
A total of 50 cases were enrolled in the study, 26(52%) were males, 24(48%) were females, and 3(6%) 
were children, with an age range between 3-65 years and a mean age of 36.39±13.57.Most of the study 
subjects 43(86%) lie between 16-55 years. (Table1). 21(42%) were married, 13(26%) were single and 
16(32%) were either widowed or divorced. The majority of the study subjects 30(60%) were coming from 
central Sudan, 6(12%) from the west, 5(10%) from the East and the rest 5(10%) were from Northern 
Sudan. When the World Health Organization (WHO) staging system was applied: 29patients (58%) were 
found to have WHO stage III disease, 16(32%) were stage IV disease, 3(6%) were stage I disease and 
2(4%) had stage II disease. (Table 2).   Risk factors for acquisition of HBV were found to be insignificant 
(Table 3). Screening for Hepatitis C Antibodies among study subjects, was negative by ELISA. Hepatitis 
B surface Antigen (HBsAg) was found to be positive in 4 patients (8%) by ELISA.  
 
Table (1): Showing the distribution of patients according to the age (N=50) 
 
Percent Total Female Male Age group 
6 3 - 3 1-15 
12 6 4 2 16-25 
28 14 6 8 26-35 
34 17 10 7 36-45 
12 6 2 4 46-55 
8 4 2 2 56-65 
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Table (2): Showing the distribution of patients according to WHO staging system (N=50)  
Percent% Total Stage 
4 2 WHO    I 
4 2 WHO   II 
56 28 WHO III 
36 22 WHO IV 
100 50 Total 
 
Table (3): Demographic Criteria of 50 subjects screened for hepatitis B Virus markers. 
 
Variable 
Gender 
Male 
Female 
Number 
tested 
HBV 
markers 
reactive% 
OR P value 
Surgery No 34 2 2.286 0.383 
Yes 16 2 
Blood transfution No 41 4 - 0.44 
Yes 9 0 
Dental treatment No 32 3 0.569 0.544 
Yes 18 1 
Sacrificaion No 10 2 4.75 0.174 
Yes 40 2 
Tattooing No 45 3 3.5 0.353 
Yes 5 1 
 
Table (4): Age group of 50 subjects screened for HBsAg by ELISA 
Age group 
ELISA 
+ve -ve 
1-15 0 3 
16-25 1 5 
26-35 2 12 
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36-45 0 17 
46-55 1 5 
56-65 0 4 
Total 4 46 
% 8% 92% 
Discussion:  
Sudan National AIDS Program (SNAP), has conducted a national survey in the year 2002 that showed the 
followings: Sudan is the most severely affected country in North Africa and the Middle East with an 
estimated 500,000 people living with HIV/AIDS, and mostly in need of antiretroviral therapy (ART). 
Despite the fact that the epidemiological data is limited, it is believed that the country is in the early 
stages of a generalized HIV/AIDS epidemic, with an almost exclusively heterosexual transmission 
pattern. The adult prevalence rate of HIV/AIDS has been estimated at 1.6%, with specific population 
group prevalence rates ranging from 0.5% to 2.5% in the northern part of the country. 
    There are no published reports on the prevalence of hepatitis B virus (HBV) and hepatitis C virus 
(HCV) among human immunodeficiency virus (HIV) positive subjects in Sudan, . However, the 
relationship between infections with these hepatitis viruses and human immunodeficiency virus (HIV) has 
not been clarified.
(7)
 
A total of 50 participants, who met the selection criteria, were enrolled in the study.  HIV infection among 
females was found to have nearly the same percentage as in males. This is similar to the global 
epidemiological statistics, despite the initial description of the disease among men who have sex with 
men (MSM) in the United States, more than 80 percent of infections occur through heterosexual 
transmission, and over 50 percent of all HIV-infected people in the world are women.
(8)
 
    Children were not excluded from HIV infection. In this study 3 (6%) were children, this pool in the 
global epidemics of HIV among children.  Globally, as of December 2005, approximately 2.3 million 
children were living with human immunodeficiency virus (HIV) infection; 570,000 children died 
secondary to HIV-associated disease during 2005 alone. (WHO/UNAIDS Geneva, Switzerland, 2002). 
Most of the study subjects 43 (86%) were in the age group between 16 -55 years, and 4 of them (8%) 
were above 56 years, and this result is nearly similar to the epidemiological facts about HIV, as it is most 
common among adults and children.
(9)
 
World Health Organization (WHO) staging system, showed that most of the patients 29 (58%) were 
WHO stage III and 16 (32%) were stage IV, which were considered the late stages of the disease. This 
late presentation is probably due to 
lack of health education, patients self referral and the problem of the social stigma, as well as to the 
behavior of the disease itself, as it mimics many other diseases that make it a late suspicion. 
    Risk factors for HIV acquisition among the study population showed a significant heterosexual 
behavior among 87.8%. This is consistent with the local data (SNAP), and nearly similar to the regional 
rates for HIV acquisition in sub-Saharan countries. In a study performed of more than 4000 men and 
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women from Rwanda and Zambia who underwent voluntary counseling and testing for HIV, an estimated 
55 to 93 percent of new heterosexually acquired HIV infections among adults occurred within 
serodiscordant marital or cohabiting relationships 
(10)
.Little is known about the overall prevalence of male 
same-sex behaviors in African societies, although there has been a surge in research in this area 
(11)
. All 
HIV-infected patients should have serologic testing for HBV, and vaccination should be initiated in 
patients who have no evidence of prior exposure 
(12)
. Early vaccination is recommended in such patients 
because HIV-infected patients with a low CD4 count have a decreased response to immunization.
(13, 14, 15, 
16)
  
In Sudan, HCV seroprevalence ranges from 2.2% in the Gezira state, an area endemic with 
schistosomiasis
 (5)
 to 4.8% in patients with schistosomal periportal fibrosis 
(6)
. In this study, hepatitis C 
turned to be negative by ELISA. This result has no similar one in this country, but nearly similar results 
were obtained in African countries. HCV/HIV co-infection was found to be 1% in Kenya 
(17)
, 5.8% in 
Nigeria 
(18)
, and 5% in Malawi 
(19)
. Despite that Sudan is classified among countries with a high hepatitis 
B surface antigen (HBsAg) endemicity of more than 8% 
(4).
The only study on HBV and human 
immunodeficiency virus (HIV) co- infection was carried out in 1987 on 593 subjects who practiced high 
risk behavior, including sexual promiscuity. Although the study showed a high prevalence of HBV 
markers (80%), none of the subjects was HIV-positive 
(7)
. In this study hepatitis B surface Antigen (HBs 
Ag) was found to be positive in 4 patients (8%) by ELISA. This remains within the national and regional 
(sub-Saharan) limits, where chronic HBV affects approximately 10 percent of HIV-infected patients 
worldwide 
(19)
. A study of 16,248 HIV-infected patients in the United States has shown the prevalence of 
chronic HBV to be eight percent among unvaccinated participants 
(20)
. Recent studies from neighboring 
African 
countries reported HBV/HIV co-infection in 6% of a studied population in Kenya
 (17)
, 9.2% in Nigeria
 (21)
, 
and 20.4% in Malawi
 (21)
.Those who tested negative for HBs Ag, need to do further tests, like HB core 
antibodies and viral DNA. Isolated anti-HBc is more common in patients with underlying HIV infection 
than in the general population 
(22, 23)
. Among those who tested positive for HBs Ag , 3 (11.5%) were 
males, and 1 (4.2%) was a female, representing a higher rate of co-infection among males in contrast to 
females. This is consistent with other studies, that have shown markers of prior HBV infection are more 
common in men who have sex with men (MSM) and injection drug users 
(20, 24)
, but this is not the case in 
both IVDU and MSM as the risk factor of co-infection was found to be (0%) for IVDU, and was almost 
exclusively heterosexual in this study. 
 
Conclusion: 
 It can be concluded that the prevalence of HBV/HIV co-infection is consistent with both regional and 
global rates, while HCV/HIV co-infection is only very near to the regional rates. HIV infected subjects 
should be screened for hepatitis B and hepatitis C, because it plays an important role in the course of the 
disease and treatment. Those who are seronegative for hepatitis B should receive hepatitis B vaccine.                                                                                              
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